Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03633838
Other study ID # D589BR00037
Secondary ID
Status Completed
Phase
First received
Last updated
Start date February 28, 2017
Est. completion date February 28, 2017

Study information

Verified date September 2018
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a Post-hoc analysis based on the database of "A non-interventional, retrospective study on AECOPD treatment status in China". A large nation-wide retrospective non-interventional study has carried out from January to September 2014 in China. The study aimed to observe clinical practice including glucocorticoids treatment in AECOPD in China. The data for 5067 cases were collected. These cases met the following inclusion criteria: more than 40 years old, diagnosed by GOLD 2013 (GOLD: The Global Initiative for Chronic Obstructive Lung Disease) as COPD at least 3 months before AECOPD based on treating physician's judgment; the patients received hospitalization due to AECOPD since Sep 2013. Demographic information, administration of corticosteroids, medical and surgical history, comorbidities, clinical outcome, laboratory tests and lung function tests were recorded in database. There were 43 sites in the main study. These sites located in 22 provinces in China. A majority of sites (40 sites) were tier 3 hospitals in major cities. The data in study was provided by each site via medical records. In 5091 screening cases, 5067 cases were recruited and included in full analysis set (FAS). All cases in FAS will be included into this post-hoc analysis.

Through data mining and analysis, it is to explore the relationship between corticosteroids based treatment regimen and clinical outcome and the optimal treatment regimen for corticosteroids used in inpatients with COPD exacerbations based on our database.


Description:

In general, the statistical analyses based on raw data and the data using propensity score matching (PSM) will be primarily descriptive in nature. The statistics are as in the following:

- Continuous variables: N, mean, standard deviation, lower quartile Q1, median, upper quartile Q3, minimum, maximum;

- Categorical variables: frequencies and percentages of patients at each category.

Before the statistical analyses, the medical history and co-morbidities need to be coded using ICD10. At the same time, the data collected should be clearly understood and provide the following information but not limited to the number of subjects enrolled in each site, the list of variables, the number of observations of each variable and the missing proportion of the variable.

The factors involved into the logistic model for propensity score matching include but not limited to demographic, baseline characteristics, severity of COPD, etc. A factor research will be performed before the matching is performed aiming to include appropriate factors into the model. Matching ratio could be exact or approximate.

Programming software is SAS 9.3 (SAS: Statistical Analysis System) or higher in Windows system. R statistical software could be another tool for the exploration.


Recruitment information / eligibility

Status Completed
Enrollment 5067
Est. completion date February 28, 2017
Est. primary completion date February 28, 2017
Accepts healthy volunteers No
Gender All
Age group 40 Years and older
Eligibility Inclusion criteria:

- Inpatients with COPD exacerbations who received Nebulized Budesonide(Neb. BUD), Systemic corticosteroids(SCS) and Neb. BUD combined with SCS treatment in 5067 cases of database were included.

Exclusion Criteria:

- The proportion of missing data for a variable at a specific site is too high to be concerned as highly variable or uncertain, then the data for this site will be excluded from the analysis.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
China Shanghai Pulmonary Hospital Shanghai Shanghai

Sponsors (1)

Lead Sponsor Collaborator
AstraZeneca

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary The length of hospital stay(days) Evaluate the clinical outcome among 3 treatment groups (1=Nebulised Budesonide (BUD), 2=Nebulised BUD+ Systemic corticosteroids (SCS), 3=SCS) day 1 to up to 30 days (Hospital discharge)
Primary The rate of mortality Evaluate the clinical outcome among 3 treatment groups (1=Nebulised Budesonide(BUD), 2=Nebulised BUD+ Systemic corticosteroids (SCS), 3=SCS) day 1 to up to 30 days (Hospital discharge)
Primary The change of FEV1(Forced Expiratory Volume in the first second) after treatment Evaluate the clinical outcome among 3 treatment groups (1=Nebulised Budesonide (BUD), 2=Nebulised BUD+ Systemic corticosteroids (SCS), 3=SCS) day 1 to up to 30 days (Hospital discharge)
Secondary The rate of new-onset pneumonia during hospitalization Evaluate the rate of new-onset pneumonia during hospitalization among 3 treatment groups (1=Nebulised BUD, 2=Nebulised BUD+ Systemic corticosteroids (SCS), 3=SCS) day 1 to up to 30 days (Hospital discharge)
Secondary The cost during hospitalization Evaluate the hospitalization cost among 3 treatment groups (1=Nebulised BUD, 2=Nebulised BUD+ Systemic corticosteroids (SCS), 3=SCS) day 1 to up to 30 days (Hospital discharge)
Secondary The age Evaluate demographic characteristics among 3 treatment groups (1=Nebulised BUD, 2=Nebulised BUD+ Systemic corticosteroids (SCS), 3=SCS) day 1 to up to 30 days (Hospital discharge)
Secondary The sex Evaluate the clinical outcome among 3 treatment groups (1=Nebulised BUD, 2=Nebulised BUD+ Systemic corticosteroids (SCS), 3=SCS) day 1 to up to 30 days (Hospital discharge)
Secondary The weight Evaluate the clinical outcome among 3 treatment groups (1=Nebulised BUD, 2=Nebulised BUD+ Systemic corticosteroids (SCS), 3=SCS) day 1 to up to 30 days (Hospital discharge)
Secondary The height Evaluate the clinical outcome among 3 treatment groups (1=Nebulised BUD, 2=Nebulised BUD+ Systemic corticosteroids (SCS), 3=SCS) day 1 to up to 30 days (Hospital discharge)
Secondary The COPD history Evaluate the clinical outcome among 3 treatment groups (1=Nebulised BUD, 2=Nebulised BUD+ Systemic corticosteroids (SCS), 3=SCS) day 1 to up to 30 days (Hospital discharge)
See also
  Status Clinical Trial Phase
Completed NCT04044625 - Effects of High-intensity Noninvasive Positive Pressure Ventilation in AECOPD N/A
Active, not recruiting NCT03751670 - Pulmonary Rehabilitation During Acute Exacerbations of Chronic Obstructive Pulmonary Disease: a Mixed-methods Approach N/A
Completed NCT03083418 - The Effect of EDP on Diaphragmatic Function and Neural Respiratory Drive in Patient With AECOPD N/A
Recruiting NCT04183530 - The Individualized Accurate Diagnosis and Treatment of Chronic Objective Pulmonary Disease(COPD) Patients Based on Multidimensional Data
Enrolling by invitation NCT06189586 - Comparison of Aerosol Inhalation and Intravenous Glucocorticoid in the Treatment of Severe AECOPD N/A
Recruiting NCT06134063 - A Clinical Study on the Efficacy and Safety of Xuanfei Baidu Granule in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease N/A
Not yet recruiting NCT06114667 - Nasal High Flow Versus Non-invasive Ventilation for Early Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease With Hypercapnic Acidosis N/A
Not yet recruiting NCT05222711 - The Use of a Monitoring Device by General Practitioners During Out-of-hours Care N/A
Recruiting NCT05480566 - Functional Strength Training and Neuromuscular Electrical Stimulation in Severe Acute Exacerbations of COPD N/A
Terminated NCT02985918 - High-Intensity vs Low-Intensity NPPV in Patients With an AECOPD: The HAPPEN Trial N/A
Recruiting NCT06175065 - Safety, PK and PD Relationships of RLS-0071 in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease Phase 2
Completed NCT04316312 - The Inspiratory Muscle Activation Pattern and Training Efficacy in Patients With Chronic Obstructive Pulmonary Disease After Acute Exacerbation N/A
Recruiting NCT04259736 - Prospective Cohort Study of Molecular Mechanism of Lower Respiratory Tract Microbes in Patients With AECOPD
Completed NCT02051166 - Clinical Practice of AECOPD Management in China N/A
Recruiting NCT04212182 - The Physiological Effect of High Flow Oxygen Therapy N/A
Not yet recruiting NCT06455670 - Effects of Chinese Medicine on Patients With Severe Acute Exacerbation of COPD N/A
Recruiting NCT04101500 - Effect of Compound Sodium Chlorate and Aminophylline Tablets on Chronic Obstructive Pulmonary Disease(COPD). Phase 4